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The HIV-1 Gag proteins are translated from the full-length HIV-1 viral RNA (vRNA), whereas the
envelope (Env) protein is translated from incompletely spliced Env mRNAs. Nuclear export of vRNAs and
Env mRNAs is mediated by the Rev accessory protein which binds to the rev-responsive element (RRE)
present on these RNAs. Evidence has shown there is a direct or indirect interaction between the Gag
protein, and the cytoplasmic tail (CT) of the Env protein. Our current work shows that env gene
expression impacts HIV-1 Gag expression and function in two ways. At the protein level, full-length Env
expression altered Gag protein expression, while Env CT-deletion proteins did not. At the RNA level,
RRE-containing Env mRNA expression reduced Gag expression, processing, and virus particle release
from cells. Our results support models in which Gag is inﬂuenced by the Env CT, and Env mRNAs
compete with vRNAs for nuclear export.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The HIV-1 envelope (Env) protein is encoded by the 30 end of the
HIV-1 viral RNA (vRNA) genome in a region that overlaps the Vpu
open reading frame (ORF), and the Tat and Rev ORFs (Adachi et al.,
1986; Li et al., 1992). Also encoded in this region is the rev responsive
element (RRE) that binds to Rev (Adachi et al., 1986; Li et al., 1992).
Ordinarily, the nuclear export signal (NES) of Rev binds to a complex
of the cellular proteins Crm1(exportin-1, XPO-1) and Ran-GTP to
facilitate the nuclear export of the HIV-1 vRNA that encodes the Gag
and GagPol proteins, as well as other incompletely spliced HIV-1
RNAs (Fischer et al., 1994, 1995, 1999; Henderson and Percipalle,
1997; Yi et al., 2002; Swanson et al., 2004, 2010; Perales et al., 2005;
Cullen, 2005; Groom et al., 2009; Sherer et al., 2011; Elinav et al.,
2012). It is noteworthy that this exit pathway differs from that of most
spliced mRNAs, which employ cellular Tap and Nxt proteins to
mediate nuclear exit (Cullen, 2005). Interestingly, the Mason-Pﬁzer
monkey virus (MPMV), a D-type retrovirus, does not encode a Rev
protein, but uses a cis-active constitutive transport element (CTE)
which binds Tap (NFX1) to foster the nuclear export of incompletely
spliced MPMV RNAs (Pasquinelli et al., 1997; Wodrich et al., 2000;
Swanson et al., 2004; Cullen, 2005).
The HIV-1 Env protein is translated from incompletely spliced
4 kb viral mRNAs to yield a glycosylated 160 kDa polyprotein (gp160)
that is routed to the plasma membranes (PM) of infected cells via the
vesicular transport pathway (Sodroski et al., 1986; Checkley et al.,
2011). During its transit, gp160 is cleaved by furin-like proteases to
yield the Env surface (SU, gp120) and transmembrane (TM, gp41)
proteins, which remain associated, and assemble into trimer units
(Welman et al., 2007; Checkley et al., 2011). At the PM, Env proteins
may be endocytosed, by virtue of internalization motifs on the TM
cytoplasmic tail (CT; Lodge et al., 1994, 1997; Egan et al., 1996; Boge
et al., 1998; Courageot et al., 1999; Chan and Chen, 2006). Alterna-
tively, Env proteins may be incorporated into assembling virus
particles. Evidence suggests that assembly of wild type (WT) Env
proteins into virus particles is dependent on an interaction between
the Env CT and the matrix (MA) domain of the precursor Gag (PrGag)
protein, but it is unclear whether this interaction is direct or indirect
(Gabuzda et al., 1992; Wang et al., 1993; Yu et al., 1993; Freed and
Martin, 1995a, 1995b, 1996; Mammano et al., 1995; Murakami and
Freed, 2000a, 2000b; Wyma et al., 2000; Santos da Silva et al., 2013).
For HIV-1 Env proteins that carry CT deletions (ΔCT), the scenerio is
different. Such ΔCT proteins do not require an interaction with MA
for virion incorporation (Gabuzda et al., 1992; Wang et al., 1993; Yu et
al., 1993; Freed and Martin, 1995a, 1995b, 1996; Mammano et al.,
1995). These observations support a model in which the long HIV-1
Env CT interferes with free diffusion into assembly sites, making it so
that ΔCT proteins are passively incorporated into virions, whereas
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WT proteins require the CT–MA interaction (Gabuzda et al., 1992;
Wang et al., 1993; Yu et al., 1993; Freed and Martin, 1995a, 1995b,
1996; Mammano et al., 1995; Murakami and Freed, 2000a, 2000b;
Wyma et al., 2000; Muranyi et al., 2013; Santos da Silva et al., 2013).
During our studies on HIV-1 assembly, we observed that
expression of HIV-1 Env proteins and RNAs exerted variable
effects on Gag protein expression, assembly, and release. In parti-
cular, we observed a protein-mediated effect, in which WT Env
protein expression reduced Gag expression and virus particle
release, while ΔCT Env protein expression did not. A second effect
was exerted at the RNA level. Speciﬁcally, we observed that
expression of Env-encoding RNAs reduced Gag expression, proces-
sing, and release, irrespective of whether the Env protein itself
was expressed. The RNA effect mapped to the RRE, and Gag
proteins that were translated from RNAs that used the Tap-
mediated nuclear exit pathway were unaffected. Overall our results
support a model for a CT–MA interaction, and demonstrate the
possibility of inhibiting HIV-1 replication via competition for RNA
nuclear export.
Results
Effects of env on HIV-1 Gag
To examine interactions between the HIV-1 structural Gag
proteins and the membrane-associated Env proteins, we initially
utilized Gag expression vectors HIV-Luc and psPAX2 (Fig. 1;
Connor et al., 1995; Zufferey et al., 1997). The former vector
employs HIV-1 (Fig. 1) control elements, and therefore expression
is controlled via the promoter in the long terminal repeat (LTR),
and the products of the viral tat and rev genes. It is noteworthy
that the env gene in this vector is non-functional due to both a
frameshift and an insertion of the ﬁreﬂy luciferase (luc) gene (De
Wet et al., 1986). In contrast to HIV-Luc, with psPAX2, the Gag and
GagPol proteins are transcribed from a spliced mRNA expressed
from a cytomegalovirus/chicken β actin (CAG) promoter, and most
of the env gene is deleted (Zufferey et al., 1997). To complement
Gag expression vectors, the HIV-1 Env protein was expressed from
SIVIIIEnv (Sullivan et al., 1995) and SIVIIIΔCT, which respectively
Fig. 1. Recombinant DNA constructs. HIV-1: shown is a map of the HIV-1 strain NL4-3 provirus with long terminal repeat (LTR) units, and the Gag, Pol Vif, Vpr (R), Vpu (U),
Env, Nef, Tat and Rev open reading frames as indicated. Also depicted is the coding region for the Env cytoplasmic tail (CT), and the Rev responsive element (RRE). HIV-Luc:
the HIV-Luc provirus is based on HIV-1 NL4-3, expresses Gag, Pol, Vif, Vpr, Vpu, Tat and Rev open reading frames, and carries the RRE element. It encodes the ﬁreﬂy luciferase
gene (Luc) between NL4-3 nt 8201 of env and nt 8443 of nef. It is env- due to a frameshift at the 50 end of env (nt 5950). HIV-gpt: the HIV-gpt provirus is based on the HIV-1
proviral clone HXB2, which is vpr-, vpu- and nef-. The HIV-gpt provirus bears a 1.2 kb deletion of the env gene (nt 6402–7620), which was replaced by a 1.1 kb fragment from
pSV2gpt, encoding an SV40 promoter and origin of replication and the E. coli xanthine–guanine phosphoribosyl transferase (gpt) gene. psPAX2: psPAX2 expresses codon-
optimized gag, and pol genes from spliced mRNAs driven by the a recombinant CMV enhancer/chicken β actin (CAG) promoter and employing the rabbit β globin
polyadenylation signal (polyA). It carries the RRE and a fragment of the env gene, but does not express the Env protein. SVIIIEnv: this HXB2 proviral derivative carries the
HIV-1 50LTR, and encodes HXB2 sequences from an artiﬁcial SalI site at nt 5496 through the 30 HXB2 LTR. The vector encodes vif, tat, rev and env, and carries an RRE. SVIIIΔCT:
SVIIIΔCT is based on SVIIIEnv, but harbors a deletion of the Env CT, by virtue of two inserted termination codons. SVIIIStop: SVIIIStop is based on SVIIIEnv, but encodes a
termination codon that truncates the Env protein after 63 codons. SVIIIpBR: the SVIIIpBR plasmid was created by replacing the HXB2 nt 5496–8470 in SVIIIEnv with a
fragment from the bacterial plasmid pBR322. It does not carry the RRE and it expresses no HIV-1 genes.
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encode WT and CT-deleted Env variants (Fig. 1): in these vectors,
Env is expressed in a Tat- and Rev-dependent manner.
To characterize the effects of WT and ΔCT Env on PrGag
expression, processing, and the release of virus-like particles
(VLP), cells were co-transfected with combinations of Gag and
Env expression constructs. Cellular and VLP Gag levels were
monitored by anti-CA immunoblotting of SDS-PAGE-fractionated
samples collected at three days post-transfection. As shown in
Fig. 2, co-transfection of either HIV-Luc or psPAX2 with a plasmid
control (bluescript –SK; Alting-Mees and Short, 1989) gave major
PrGag, p41 and CA bands in both cell and VLP samples. We also
observed additional, less pronounced bands, particularly with the
psPAX2 plasmid, which we infer to be Gag or GagPol processing
products, as they were not present in mock-transfected or
SVIIIEnv-only-transfected samples (data not shown). Surprisingly,
co-transfection of HIV-Luc or psPAX2 with Env expression vectors
gave signiﬁcantly different results. In particular, co-transfection of
HIV-Luc with either SVIIIEnv or SVIIIΔCT reduced cellular Gag
levels to 18–20% control levels (Fig. 2, right panel), dramatically
reduced cellular PrGag processing (Fig. 2, left panel), and almost
eliminated VLP Gag signals (Fig. 2, center panel). These observa-
tions are examined in more detail in sections below. In contrast to
HIV-Luc, co-transfection of psPAX2 with SVIIIΔCT appeared to
have little effect on cellular and VLP Gag levels, relative to the
control. However, psPAX2-directed Gag expression and VLP release
were reduced to approximately 60% and 35% in SVIIIEnv co-
transfections (Fig. 2, right panel). These results indicate a CT-
dependent effect on Gag levels, consistent with previous observa-
tions that full-length Env protein expression may alter Gag
trafﬁcking patterns and/or may be toxic to cells (Sodroski et al.,
1986; Lodge et al., 1994, 1997; Chakrabarti et al., 2002; Chan and
Chen, 2006; Checkley et al., 2011; Santos da Silva et al., 2013).
RNA level effects on Gag protein expression and release
As shown in Fig. 2, co-transfection of either SVIIIEnv or
SVIIIΔCT with HIV-Luc reduced cellular PrGag expression, proces-
sing and release. To ascertain whether similar effects were exerted
on wild type HIV-1, SVIIIEnv variants were co-expressed with a
plasmid expressing the WT HIV-1 NL4-3 (Adachi et al., 1986)
provirus. As with HIV-Luc, we found that PrGag processing was
reduced relative to controls when NL4-3 was co-transfected with
SVIIIEnv or SVIIIΔCT expression vectors, even though NL4-3 also
encodes env (Fig. 3, left panel). Moreover, the Env expression
vectors reduced both cellular total Gag levels and VLP release
(Fig. 3, right panel). Similar effects also were obtained with the
recombinant HIV-gpt (Fig. 1; Page et al., 1990) Gag/GagPol expres-
sion vector (data not shown). These effects were not dependent on
Env protein expression, because similar effects were observed in
co-transfections with the SVIIIStop plasmid, in which Env transla-
tion is terminated after 62 residues. However, the effect was not
observed when the SVIIIEnv env gene was replaced by a hetero-
logous sequence in SVIIIpBR (Fig. 3), suggesting that regulation
might occur at the RNA level.
Based on the above results, co-transfections of NL4-3 were
performed with env gene-deleted SVIIIStop variants to localize the
element(s) responsible for NL4-3 Gag protein down-regulation.
Importantly, somewhat reduced cellular Gag protein levels and
signiﬁcantly reduced VLP-associated Gag protein levels were
observed with SVIIIStop and the Δ5496–6348, Δ6348–7075, and
Δ8136–8470 variants, but not with the Δ7075–8136 variant
(Fig. 4). Notably, the deleted sequence in the Δ7075–8136 con-
struct includes the RRE, suggesting a competition of SVIIIEnv RNAs
with the full-length HIV-1 viral RNA (vRNA) for nuclear export
mediated by the Rev-Crm1 pathway.
That SVIIIEnv RNAs might compete with vRNAs for nuclear
export was consistent with observations that HIV-Luc, HIV-gpt,
and NL4-3 HIV-1 (Fig. 1) were down-regulated, but spliced Gag
messages expressed from psPAX2 were not (Fig. 2). To examine
this further, we compared SVIIIStop effects on RNAs transported by
different nuclear export pathways. To do so, control or SVIIIStop
plasmids were co-transfected into cells with GPV-RRE, which
depends on the Rev-Crm pathway (Swanson et al., 2004); or with
GPV-4xCTE or GPV-RevInd, both of which utilize the Tap nuclear
export pathway (Kotsopoulou et al., 2000; Swanson et al., 2004).
Our results (Fig. 5) clearly showed that co-expression with the
RRE-containing SVIIIStop construct markedly reduced cellular and
VLP Gag levels from the GPV-RRE vector, but not from GPV-4xCTE
or GPV-RevInd. These data support the notion that RRE-containing
env mRNAs can compete with HIV-1 vRNAs for nuclear export.
in situ localization of HIV-1 vRNA
The above results suggested that the RRE-containing RNAs alter
the fate of HIV-1 vRNAs after transcription. Therefore, we decided
to analyze the localization of vRNAs in transfected cells. Initially,
we measured total cellular full-length HIV-Luc vRNA levels by
reverse transcription and polymerase chain reactions (PCR). These
experiments showed that total cellular HIV-Luc vRNA levels were
marginally higher (10779%; N¼4) in co-transfections with SVIII-
Stop (RREþ) versus SVIIIpBR (RRE). Next, we attempted to
measure nuclear and cytoplasmic vRNA levels by cell fractionation,
Fig. 2. Env expression effects on Gag protein expression and particle release. HEK 293 T cells (5 million on each 10 cm plate) were transfected with 12 mg of the indicated
HIV-Luc or psPAX2 constructs in conjunction with 12 mg of the –SK (control), SVIIIEnv or SVIIIΔCT plasmid constructs. At 72 h post-transfection, cell lysate and virus particle
samples were collected, fractionated by SDS-PAGE, and electroblotted. Gag proteins in fractionated samples were detected by immunoblotting using an antibody to HIV-1 CA.
In the left two panels, PrGag, p41 and CA bands are indicated. In the rightmost panel, cellular and viral Gag bands were quantiﬁed densitometrically and normalized against
the Gag levels obtained in control (plus –SK) transfections. The results represent values obtained from at least two independent experiments. Standard deviations are as
indicated.
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RNA isolation, and detection via reverse-transcription and
polymerase chain reactions. However, this approach proved
inadequate, possibly due to variability in fractionations. As an
alternative, we employed ﬂuorescence in situ hybridization
(FISH) methods. For these experiments, cells were transfected
with the HIV-Luc construct, and either SVIIIpBR or SVIIIStop, and
then processed for dual detection of HIV-1 capsid proteins (by
immunoﬂuorescence) and vRNA (by FISH). The vRNAs were detected
using a digoxin-labeled probe against HIV-1 pol (nt 2250–2687),
followed by detection using a mouse anti-digoxin antibody, and
a ﬂuoresecently-tagged anti-mouse antibody. In this assay, because
the vDNA is not denatured, labeling is speciﬁc for the vRNA (Lai
et al., 2013).
In Fig. 6, images from un-transfected cells (mock) or from cells
transfected with HIV-Luc plus either SVIIIpBR or SVIIIStop are
shown. In each case, the CA immunoﬂuorescence signal is in red,
and the vRNA signal is green. As shown in the left hand panel,
signals in un-transfected cells (mock) were below levels of detec-
tion, unless images were over-exposed (mock over-exposed), in
which case cell outlines were faintly observable. For transfected
cells, as expected, CA signals were cytoplasmic. Also, consistent
with observed reduced Gag signals in cells co-transfected with
RRE-containing SVIIIEnv variants (Figs. 2–5), CA immunoﬂuores-
cence signals were fainter in SVIIIStop co-transfections than
SVIIIpBR co-transfections. Importantly, vRNA localization patterns
differed as well. With the SVIIIpBR co-transfections, green and
yellow vRNA FISH signals were predominantly cytoplasmic. In
contrast, images acquired for the SVIIIStop transfections showed a
predominant nuclear accumulation of the HIV-Luc vRNA (green
signal). To quantify results, over 30 images each of cells transfected
with HIV-Luc and either SVIIIpBR or SVIIIStop were analyzed to
determine cytoplasmic:nuclear HIV-Luc vRNA localization ratios as
described in Materials and methods. The resulting values and
means are graphed in Fig. 6 (right hand panel). As shown,
expression of HIV-Luc in the presence of SVIIIStop, which carries
the RRE, resulted in a lower cytoplasmic accumulation of the HIV-
Luc vRNA than did the SVIIIpBR control. Statistical analysis using
an unpaired t-test indicated a signiﬁcant difference in vRNA
localization patterns between the two sets of samples. These
results indicate that an RRE sequence present on a co-
transfected plasmid reduced HIV-1 vRNA nuclear export, and are
consistent with reduced cellular and VLP Gag levels observed in
co-transfections with RRE-containing SVIIIEnv derivatives in
Figs. 2–5.
Effects of Gag levels on VLP release
In the course of our studies, we observed considerably greater
effects of RRE competition on VLP release levels than on cellular
Gag levels (Figs. 2–5). Potentially, such results could indicate that
proteins translated from HIV-1 vRNAs in the presence or absence
of export competitor RNAs may have qualitatively different fates
(Swanson et al., 2004). Alternatively, the more drastic reductions
in VLP release levels than cellular Gag levels in the presence of
RRE-containing competitors may simply reﬂect the possibility that
virus release is not linearly proportional to intracellular Gag levels
(Sherer et al., 2011). To test these alternatives, cells were trans-
fected with decreasing amounts of HIV-1 NL4-3 plasmid, after
which cellular and VLP-associated Gag levels were determined.
As depicted in Fig. 7, as much as an eight-fold reduction in trans-
fected NL4-3 plasmid only reduced cellular Gag levels 2- to 3-fold.
In contrast, a two-fold reduction in transfected plasmid reduced
VLP-associated Gag levels approximately three-fold, and an eight-
fold reduction of transfected plasmid yielded at least a 20-fold
reduction in VLP Gag signals (Fig. 7). These data are compatible
with the notion that the observed reductions of VLP Gag are a
direct consequence of reduced cellular Gag levels, but do not rule
out the possibility that perturbation of vRNA nuclear export
pathways may confer qualitatively different Gag protein fates.
Discussion
The env coding region at the 30 end of the HIV-1 genome
impacts virus particle release at the protein level and at the RNA
level. Previous work has demonstrated an interaction between
HIV-1 Env and the MA domain of PrGag (Gabuzda et al., 1992;
Wang et al., 1993; Yu et al., 1993; Freed and Martin, 1995a, 1995b,
1996; Mammano et al., 1995; Murakami and Freed, 2000a, 2000b;
Wyma et al., 2000; Santos da Silva et al., 2013). A number of
studies have shown that incorporation of WT Env proteins into
virus particles requires a direct or indirect interaction with MA,
supporting a model in which PrGag MA domains usher Env
proteins into virions through an association with the Env CT tail
Fig. 3. Effects of env gene variants on Gag expression, processing, and release. HEK 293 T cells (5 million on each 10 cm plate) were co-transfected with 12 mg of the NL4-3
HIV-1 proviral plasmid in conjunction with 12 mg of the –SK (control), SVIIIEnv, SVIIIΔCT, SVIIIpBR or SVIIIStop plasmids. At 72 h post-transfection, cell lysate and virus
samples were collected, and subjected to SDS-PAGE and electroblotting. Gag proteins were detected by immunoblotting using a primary anti-MA antibody, and in the left
two panels, PrGag and MA proteins are indicated, along with a non-speciﬁc cross-reactive cellular protein (*). For quantitation (right hand panel), cellular and viral Gag levels
were determined densitometrically and normalized against the control. The results are the values obtained using duplicates of two independent transfections. Standard
deviations are as shown.
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(Gabuzda et al., 1992; Wang et al., 1993; Yu et al., 1993; Freed and
Martin, 1995a, 1995b, 1996; Mammano et al., 1995; Murakami and
Freed, 2000a, 2000b; Wyma et al., 2000; Checkley et al., 2011;
Santos da Silva et al., 2013). It also is noteworthy that HIV-1 Env
inﬂuences the sub-cellular localization of PrGag proteins, and that
this effect is dependent, at least in part, on a YSPL endocytic motif
on the Env CT (Lodge et al., 1994, 1997; Egan et al., 1996; Boge et
al., 1998; Courageot et al., 1999; Chan and Chen, 2006). The
situation is different with ΔCT HIV-1 Env proteins, which appear
to be passively incorporated into HIV-1 particles, presumably
because they localize to the proximity of assembly sites (Freed
and Martin, 1995a, 1995b; Mammano et al., 1995; Murakami and
Freed, 2000a, 2000b; Checkley et al., 2011; Santos da Silva et al.,
2013). Our results with co-transfected psPAX2 and WT or ΔCT Env
protein expression vectors clearly show a CT-dependent effect of
the HIV-1 Env protein on Gag protein cellular levels, localization,
and release (Fig. 2). Speciﬁcally, expression of the psPAX2 vector
with WT SVIIIEnv, but not SVIIIΔCT reduced cellular levels of
PrGag, as well as virus release levels (Fig. 2). These data are
consistent with previous observations that WT Env directs PrGag
Fig. 4. Mapping of the trans acting element affecting Gag protein expression and virus particle release. The left hand diagram depicts the SVIIIStop parental construct, and its
four deletion derivatives, Δ5496–6348, Δ6348–7075, Δ7075–8136, and Δ8136–8474. Twelve micrograms of these plasmids or the control plasmid (–SK) were co-transfected
into 5 million HEK 293 T cells on 10 cm plates along with 12 mg of the NL4-3 HIV-1 proviral plasmid, and cell and virus samples were collected at 72 h for Gag protein
detection as described in Fig. 3. The bottom panels show immunoblots of cell and virus samples using a primary antibody to HIV-1 CA. Cellular and viral Gag levels were
quantitated densitometrically from duplicates of two independent transfections, normalized versus the NL4-3 plus –SK control transfections, and are plotted in the graph on
the upper right hand side with standard deviations as indicated. Note that in transfections with the Δ7075–8136 derivative, which lacks the RRE, cellular and viral Gag levels
are approximately those of the control.
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localization and stability either directly or indirectly (Sodroski
et al., 1986; Lodge et al., 1994, 1997; Chakrabarti et al., 2002; Chan
and Chen, 2006; Checkley et al., 2011; Santos da Silva et al., 2013).
Our data also show that expression of HIV-1 Env RNAs inter-
fered with Gag expression from HIV-1 proviral constructs includ-
ing HIV-Luc (Fig. 2), HIV-gpt (data not shown), and the NL4-3 WT
strain (Figs. 3 and 4). We observed effects that ranged from 30%
to ﬁve-fold reductions in cellular Gag levels, with much more
signiﬁcant decreases in PrGag processing and Gag protein release
(Figs. 2–4). The effects of Env RNAs on PrGag were independent of
the CT (SVIIIΔCT; Figs. 2 and 3) and even Env protein translation
(SVIIIStop; Figs. 3 and 4), and mapped to the RRE (Δ7075–8136,
Fig. 4). That expression of RRE-containing transcripts in trans
appeared to regulate PrGag levels suggested a competition for
the Rev-mediated nuclear export pathway might be responsible
for these results (Fischer et al., 1994, 1995, 1999; Henderson and
Percipalle, 1997; Yi et al., 2002; Swanson et al., 2004, 2010; Perales
et al., 2005; Cullen, 2005; Groom et al., 2009; Sherer et al., 2011;
Elinav et al., 2012). Our in situ localization of HIV-Luc vRNAs in
cells co-transfected with SVIIIStop versus SVIIIpBR supports this
interpretation (Fig. 6). Speciﬁcally, relative to SVIIIpBR, which does
not encode an RRE, co-transfection of RRE-encoding SVIIIStop with
HIV-Luc reduced nuclear export of HIV-Luc vRNAs, and Gag
expression levels (Fig. 6). Consistent with the RRE competition
model, HIV-1 Env RNA expression did not appreciably affect Gag
levels from GPV-4xCTE RNAs (Fig. 5), which employ MPMV CTEs to
direct vRNA nuclear export via the Tap pathway (Pasquinelli et al.,
1997; Wodrich et al., 2000; Swanson et al., 2004; Cullen, 2005),
or from spliced psPAX2 or GPV-RevInd RNAs (Figs. 2 and 5), which
also presumably exit the nucleus via the Tap pathway (Swanson
et al., 2004).
At this point, it is unclear as to which factor in the Rev-Crm1
nuclear export pathway might be limiting, and thus responsible
for the observed competition in RRE-mediated cytoplasmic deliv-
ery of vRNAs. Conceivably, the limiting factor could be Rev, the
cellular factors Crm1 or Ran-GTP, or other known (RanBP3, DDX3,
RanBP2, NUP358) or unknown members of the pathway (Fischer
et al., 1994, 1995, 1999; Henderson and Percipalle, 1997; Yi et al.,
Fig. 5. Effects of SVIIIStop on alternative HIV-1 Gag expression constructs. Depicted in the upper panel are three alternative Gag and GagPol expression plasmids that all
employ the cytomegalovirus (CMV) promoter and the SV40 polyadenylation signal (AAA), and have splice donor (SD) and splice acceptor (SA) sites. The GPV-RRE plasmid
encodes HIV-1 gag, pol, vif and vpr (R) genes, and carries a copy of the RRE. GPV-4CTE is similar to GPV-RRE, but carries four copies of the Mason Pﬁzer monkey virus
(MPMV) constitutive transport element (CTE) in place of the RRE. GPV-RevInd expresses codon-optimized Gag and Gag-Pol proteins from a spliced message that is Rev and
RRE independent. Twelve micrograms of these plasmids were separately co-transfected onto 10 cm plates of 5 million HEK 293 T cells with either 12 μg of SVIIIStop, which is
Revþ and RREþ , or 12 μg of Δ7075–8136 (Fig. 4), which is Revþ and RRE . At 72 h post-transfection cell and viral Gag proteins were detected and quantiﬁed as described
in Fig. 3. The lower left panels show immunoblots of cell and virus samples using a primary antibody to HIV-1 CA, and results are plotted in the lower right panel as the ratios
of cellular or viral Gag levels obtained in co-transfections with RREþ versus RRE constructs. Results represent values obtained using duplicates of two independent
transfections, and standard deviations are as shown.
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2002; Swanson et al., 2004, 2010; Perales et al., 2005; Cullen,
2005; Groom et al., 2009; Sherer et al., 2011; Elinav et al., 2012).
It is also unclear as to whether the drastic reductions we have
observed in PrGag processing and release directly reﬂect cellular
PrGag levels, or whether other nuclear export pathway-speciﬁc
effects are at play. Our data (Fig. 7) and the data of others (Sherer
et al., 2011) suggest that PrGag release levels are not linearly
proportional to cellular PrGag levels, but that this is a pathway-
independent phenomenon. Nevertheless, it remains possible that
variations in nuclear exit strategies, or effects on host factors
impacting stabilities, modiﬁcations, or trafﬁcking may inﬂuence
the fates of messages and their translation products (Swanson et
al., 2004; Cullen, 2005; Sherer et al., 2009; Jin et al., 2009). In
either case, our data strongly support the idea that inhibition of
HIV-1 vRNA nuclear export is a potentially viable anti-viral
approach (Mautino and Morgan, 2002; Ward et al., 2009; Wong
et al., 2013).
Materials and methods
Recombinant DNA constructs
The parental HIV-Luc (pNL-LucE-Rþ) (Connor et al., 1995) and
HIV-gpt (Page et al., 1990) constructs were kindly provided by
Nathaniel Landau. The HIV-1 NL4-3 molecular clone (Adachi et al.,
1986), and psPAX2 (pCMVdeltaR8.91) and SVIIIEnv vectors
(Zufferey et al., 1997; Sullivan et al., 1995) were obtained from
the NIH AIDS reagent program. GVP-RRE, GPV-4xCTE and GPV-
RevInd (Kotsopoulou et al., 2000) were kindly provided by Michael
Malim (Swanson et al., 2004). SVIIIΔCT was created by cloning the
SalI–BamHI band (nt 5785–8465) from pNL4-3ΔCT144 (Freed and
Martin 1995a; 1995b), in which the C-terminal 144 amino acids
from gp41 were removed, into the SalI–BamHI sites of SVIIIEnv:
the Env protein is thus truncated at the beginning of the CT at
residues SIVNR VRQGY X. SVIIIStop was created by a DNA insertion
at the NdeI site of env (HXB2 nt 6401). The sequence at the NdeI
site (shown in italics) is GCA TAT GAT TAA TAT CTA GAG CAT ATT
ATG, where the TAA stop codon that truncates Env after 63 codons
is indicated in bold. SVIIIpBR was created by replacing the SalI–
BamHI fragment (nt 3610–6130) of the SVIIIEnv (corresponding to
HXB2 nt 5496–8470) by the SalI–BamHI fragment of the pBR322
plasmid (nt 651–375; Bolivar et al. 1977). The Δ5496–6348,
Δ6348–7075, Δ7075–8136 and Δ8136–8470 vectors represent
deletions of SVIII at the indicated HXB2 sequences and were
generated by standard molecular biology procedures. In Δ5496–
6348, the SalI–KpnI fragment was replaced by an oligo yielding the
sequence GTC GAC CCC GGG GGT ACC. In Δ6348–7075, the KpnI–
PvuII fragment was replaced by an oligo yielding the sequence
GGT ACC CCC GGG CAG CTG. In Δ7075–8136, the PvuII–HindIII
fragment was replaced by an oligo yielding the sequence CAG CTG
CCC GGG CAA GCT T. In this vector the RRE sequence is no longer
present. In Δ8136–8470, the HindIII–BamHI fragment was
replaced by an oligo yielding the sequence AAG CTT CCC GGG
GGA TCC.
Cell culture, transfections and immunoblotting
HEK 293 T (DuBridge et al., 1987) cells were maintained in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 10 mM HEPES (pH 7.4), penicillin,
and streptomycin at 37 1C and 5% CO2. Analysis of cellular protein
expression and virus particle assembly and release was performed
at 48–72 h after calcium phosphate transfections of HEK 293 T
cells (5 million cells on 10 cm plates) by using a total of 24 μg
plasmid DNA constructs as described previously (Scholz et al.,
2005, 2008; Noviello et al., 2011; López et al., 2013). All such
experiments were performed at least twice with at least two
different plasmid DNA preparations. Virus samples were collected
by ﬁltering media supernatants through 0.45 μm ﬁlters, followed
by pelleting through 20% sucrose cushions in phosphate-buffered
saline (9.5 mM sodium potassium phosphate [pH 7.4], 137 mM
NaCl, 2.7 mM KCl) for 2 h at 100,000g at 4 1C (Scholz et al., 2005,
2008; Noviello et al., 2011; López et al., 2013). Pelleted viruses
were carefully resuspended in cold PBS and stored at 80 1C. Cells
were washed in cold PBS and then lysed in cold IPB (20 mM Tris–
hydrochloride [pH 7.5], 150 mM NaCl, 1 mM EDTA, 0.1% sodium
Fig. 6. Fluorescent in situ hybridization (FISH) analysis. HEK 293 T cells (5 million
on each 10 cm plate) were co-transfected with 12 mg of HIV-Luc and 12 mg of either
SVIIIpBR or SVIIIStop. At 48 h post-transfection, cells were split onto Permanox
chamber slides (Nalge Nunc International) at a 1:20 ratio and incubated for 24 h
and then processed for FISH analyses as described in Materials and methods. For
detection of HIV-1 Gag, a primary anti-CA antibody was used in conjunction with a
secondary Alexa Fluor 568-conjugated (red) anti-mouse antibody. To detect the
viral RNA, a digoxin-labeled probe against HIV-1 pol (nt 2250–2687) was employed,
and detected with a primary anti-digoxin antibody, and a secondary Alexa Fluor
488-conjugated (green) antibody. In the far left panels, images from un-transfected
cells (mock) are shown, using either standard imaging conditions, or with double
the standard brightness value (mock over-exposed) to show the faint outlines of
the cells. Also shown are examples of cells transfected with HIV-Luc plus SVIIIpBR
or SVIIIStop. Note the predominant nuclear vRNA (green) staining for the SVIIIStop
versus the SVIIIpBR transfections. In the right hand panel, individual cells were
scored for cytoplasmic versus nuclear viral RNA (vRNA) FISH signals, and cyto-
plasmic/nuclear ratios so obtained were graphed on the scatter plot, along with the
group mean values. The unpaired t-test value (p¼0.0001) indicates a signiﬁcant
difference in the cytoplasmic versus nuclear ratios in cells co-transfected with the
SVIIIpBR (RRE) versus SVIIIStop (RREþ) plasmids.
Fig. 7. Comparison of cellular and viral Gag protein levels. Various amounts of the
HIV-1 NL4-3 proviral plasmid (16, 8, 4 and 2 mg) were used to transfect 10 cm plates
of 5 million HEK 293 T cells in parallel. For each transfection, the total amount of
DNA transfected was normalized to 24 mg by the addition of –SK carrier plasmid.
At 72 h post-transfection, cell and viral samples were subjected to electrophoresis
and immunoblotting with an anti-CA antibody (left hand panels). Gag levels in cell
and viral samples from two independent experiments were quantiﬁed as described
in Materials and methods, and results are plotted as percentages of the maximum
cellular or viral Gag levels obtained.
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dodecyl sulfate [SDS], 0.5% sodium deoxycholate, 1.0% Triton
X-100, 0.02% sodium azide). To remove insoluble debris, lysates
were centrifuged at 4 1C for 15 min at 13,000g. Supernatants were
collected and stored at 80 1C prior to use. Both virus and cell
samples were mixed with equal volumes of 2 sample loading
buffer (12.5 mM Tris–HCl [pH 6.8], 2% SDS, 20% glycerol, 0.25%
bromphenol blue, 10% β-mercaptoethanol), fractionated via 10–
12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and elec-
troblotted onto nitrocellulose (BioRad Laboratories). For HIV-1 Gag
protein immunoblotting, a mouse anti-CA monoclonal antibody
Hy183 (kindly provided by Bruce Chesebro) was used at a 1:10
dilution (from culture media) or an anti-MA antibody (Capricorn
Products; HIV-018-48170) was used at a 1:800 dilution. Detection
of Gag proteins was achieved using a secondary alkaline
phosphatase-conjugated anti-mouse antibody (Promega) at a
1:10,000 dilution, and subsequent color reactions for visualization
of antibody-bound bands with nitroblue tetrazolium plus
5-bromo-4-chloro-3-indolyl phosphate in 100 mM Tris–hydro-
chloride (pH 9.5), 100 mM NaCl, and 5 mM MgCl2. Cell and virus
Gag levels were quantiﬁed densitometrically using NIH ImageJ
software.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) experiments were
performed on transfected HEK 293 T cells at 72 h post-
transfection. All the steps were performed using RNase free
solutions containing 2 mM vanadyl ribonucleoside (VRC). The
DNA pol gene probe was prepared by asymmetric-PCR using
Pol2687 reverse primer 50-TTTCC CTTCC TTTTC CATCT CTG-30,
Gag2250 forward primer, 50-TTCCC TCAGG TCACT CTTTG GC-30,
HIV-gpt plasmid as template, and a PCR-DIG Probe Synthesis Kit
(Roche Diagnostics). For FISH incubations, transfected HEK 293 T
cells were split 24 h post transfection onto Nunc Lab-Tek Chamber
Slide system slides, previously treated with 0.3 ml polylysine
(0.1 mg/ml; Sigma) for 30 min at 37 1C, and washed and incubated
in complete media (DMEM, 10% FBS). At 72 h post-transfection,
cells were washed twice with 0.5 ml PBS, and then ﬁxed with 5%
formaldehyde, 2 mM VRC and 2% sucrose in PBS for 20 min at
room temperature. After three washes with PBS, cells were
permeabilized with 0.25% Triton X-100 in PBS for 10 min at room
temperature. Permeabilized cells were then pre-incubated with
hybridization solution (Sigma H7140) containing the following
constituents: 100 μg/ml DNA, 5 SSC (1 SSC¼150 mM NaCl,
15 mM sodium citrate), 1Denhardt's solution (0.02% BSA, 0.02%
ﬁcoll 400, 0.02% polyvinylpyrrolidone), 50% formamide, 5 mM
dithiothreotol (DTT), 2 mM VRC. This pre-incubation step was for
30 min at 45 1C, and the hybridization solution had previously
been heated to 75 1C for 10 min for denaturation. After pre-
incubations, hybridizations were performed with 0.2 ml of
400 ng/ml probe (previously denatured at 75 1C for 10 min, and
then quenched on ice for 3 min) in hybridization solution over-
night at 50 1C in humidiﬁed chambers. Cells next were washed
twice, 5 min each, with 45% formamide, 2 SSC, 2 mM VRC at
45 1C; once with 2 SSC, 2 mM VRC at 45 1C for 15 min, and once
with 2 SSC, 2 mM VRC at room temperature for 10 min. Cells
then were incubated with a mouse anti-digoxin monoclonal anti-
body (IgG fraction; Jackson Immuno Research Laboratories, Inc.) at
a 1:200 dilution in 4 SSC, 2 mM VRC and 1% BSA for 2 h at room
temperature. After three washes, secondary antibody incubation
was for 1 h at room temperature using an Alexa Fluor 488-
conjugated goat anti-mouse antibody (Life Technologies) at a
1:1000 dilution. After this step, cells were washed three times
with complete media, and incubated with the undiluted anti-CA
Hy183 monoclonal antibody for 2 h at room temperature, followed
by three complete media washes, and a 1 h, room temperature
secondary antibody incubation, using Alexa Fluor 568-conjugated
goat anti-mouse IgG (Life Technologies) at a 1:1000 dilution in
complete media. Following these incubations, the cells were
washed twice with complete media followed by two washes in
PBS. Cells then were incubated in cold methanol (100%) for 10 min
at room temperature, followed by one wash in PBS. Coverslips so
treated were mounted using FluoroGuard antifade reagent (Bio-
Rad Laboratories) and imaged on a Zeiss Axiovert 200 M decon-
volution microscope equipped with Chroma ﬁlters 41,001 (excita-
tion 480 nm, emission 535 nm) and 41,004 (excitation 560,
emission 645 nm). Images were acquired using a 40x objective
lens on an AxioCam MRm Zeiss camera. Stacks of images were
analyzed using the AxioVision Zeiss software. Alternatively,
images were collected on a Zeiss Axio Observer Z1 inverted
microscope as described in the immunoﬂuorescence section
above. For ﬂuorescence intensity quantitation of the vRNA signals
in acquired images, Image J software was utilized. Brieﬂy, nuclear
and cellular boundaries were selected by hand, and mean bright-
ness values for vRNA FISH signals were quantiﬁed to obtain
nuclear and total cell areas and mean ﬂuorescence brightness
values. Cytoplasmic brightness values were determined by the
formula cytoplasmic mean brightness¼[(total cell areamean
cell brightness)(nuclear area mean nuclear brightness)]/(total
areanuclear area). For statistical purposes, data obtained from
these images were plotted using Prism5 software. Differences
were calculated to be signiﬁcant to a P value of o0.0001, using
the unpaired two-tailed t test calculation function of Prism5.
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